{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:09:32Z","timestamp":1794658172191,"version":"4.9.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ucl.2025.09.009","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:01:14Z","timestamp":1763643674000},"page":"99-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Active Surveillance for Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Laurence","family":"Klotz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ucl.2025.09.009_bib1","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0022-5347(05)65174-9","article-title":"Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and\/or clinical progression","volume":"167","author":"Choo","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.009_bib2","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","article-title":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","volume":"324","author":"Catalona","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.009_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2002.20.2.557","article-title":"Comprehensive comparison of health-related quality of life after contemporary therapies in localized prostate cancer","volume":"20","author":"Wei","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.009_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrurol.2016.251","article-title":"The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA","volume":"14","author":"Fleshner","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MOU.0000000000000383","article-title":"Impact of the United States preventive services task force \u2018D\u2019 recommendation on prostate cancer screening and staging","volume":"27","author":"Eapen","year":"2017","journal-title":"Curr Opin Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.009_bib6","article-title":"Analysis of active surveillance uptake for localized prostate cancer in Quebec in 2016: a Canadian bicentric study and comparison with 2010 data","volume":"34","author":"Dariane","year":"2024","journal-title":"Fr J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of AS for management of low-risk prostate cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.009_bib8","first-page":"135","article-title":"Using AS for gleason 7 (3+4) prostate cancer: a narrative review","volume":"18","author":"Bernardino","year":"2024","journal-title":"Can Urol Assoc J"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib9","first-page":"439","article-title":"High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic ade- nocarcinoma between the ages of 20\u201369: an autopsy study of 249 cases","volume":"8","author":"Sakr","year":"1994","journal-title":"Vivo"},{"issue":"14","key":"10.1016\/j.ucl.2025.09.009_bib10","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/jnci\/djt151","article-title":"Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men","volume":"105","author":"Zlotta","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ucl.2025.09.009_bib11","unstructured":"Canadian Cancer Society. Canadian Cancer Statistics 2024. 2024. Available at: https:\/\/cancer.ca\/en\/research\/cancer-statistics. (Internet). Available at: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/prostate\/statistics"},{"key":"10.1016\/j.ucl.2025.09.009_bib12","unstructured":"American Cancer Society. Cancer Facts & Figures 2025. Atlanta: American Cancer Society; 2025. Available at https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2025-cancer-facts-figures.html (Internet). Available at: https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/about\/key-statistics.html."},{"issue":"1","key":"10.1016\/j.ucl.2025.09.009_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.009_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(12)70388-1","article-title":"Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?","volume":"13","author":"Ahmed","year":"2012","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ucl.2025.09.009_bib15","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/pros.21373","article-title":"Gene expression pathways of high grade localized prostate cancer","volume":"71","author":"Ross","year":"2011","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.ucl.2025.09.009_bib16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrurol.2016.141","article-title":"Does true Gleason pattern 3 merit its cancer descriptor?","volume":"13","author":"Miah","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ucl.2025.09.009_bib17","doi-asserted-by":"crossref","first-page":"10991","DOI":"10.1073\/pnas.0603678103","article-title":"A molecular correlate to the Gleason grading system for prostate adenocarcinoma","volume":"103","author":"True","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ucl.2025.09.009_bib18","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/pros.21504","article-title":"Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene","volume":"72","author":"Fleischmann","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.ucl.2025.09.009_bib19","first-page":"4730","article-title":"Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation","volume":"9","author":"Padar","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2025.09.009_bib20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1054\/bjoc.2001.1971","article-title":"Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer","volume":"85","author":"West","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ucl.2025.09.009_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00345-009-0471-4","article-title":"Prognostic value of microvessel density in prostate cancer: a tissue microarray study","volume":"28","author":"Erbersdobler","year":"2010","journal-title":"World J Urol"},{"key":"10.1016\/j.ucl.2025.09.009_bib22","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1158\/0008-5472.CAN-05-3082","article-title":"Evolution of the androgen receptor pathway during progression of prostate cancer","volume":"66","author":"Hendriksen","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2025.09.009_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/modpathol.3800981","article-title":"Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer","volume":"21","author":"Furusato","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ucl.2025.09.009_bib24","doi-asserted-by":"crossref","first-page":"8347","DOI":"10.1158\/0008-5472.CAN-06-1966","article-title":"Expression of variant TMPRSS2\/ERG fusion messenger RNAs is associated with aggressive prostate cancer","volume":"66","author":"Wang","year":"2006","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ucl.2025.09.009_bib25","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/modpathol.2016.63","article-title":"PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for AS","volume":"29","author":"Trock","year":"2016","journal-title":"Mod Pathol"},{"issue":"27","key":"10.1016\/j.ucl.2025.09.009_bib26","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.22.00123","article-title":"Low-Grade prostate cancer: time to stop calling it cancer","volume":"40","author":"Eggener","year":"2022","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.ucl.2025.09.009_bib27","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1200\/JCO.22.00926","article-title":"Renaming gleason score 6 prostate to noncancer: a flawed idea scientifically and for patient care","volume":"40","author":"Epstein","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2025.09.009_bib28","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.22.01621","article-title":"Redefining gleason 6 prostate cancer nomenclature: the surgeon\u2019s perspective","volume":"41","author":"Baboudjian","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ucl.2025.09.009_bib29","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/PAS.0b013e3182556dcd","article-title":"Do adenocarcinomas of the prostate with gleason score (GS) \u22646 have the potential to metastasize to lymph nodes?","volume":"36","author":"Ross","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib30","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.juro.2010.10.057","article-title":"Predicting 15-year prostate cancer specific mortality after radical prostatectomy","volume":"185","author":"Eggener","year":"2011","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.009_bib31","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/sim.6003","article-title":"Modeling grade progression in an AS study","volume":"33","author":"Inoue","year":"2014","journal-title":"Stat Med"},{"issue":"20","key":"10.1016\/j.ucl.2025.09.009_bib32","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.2010.33.0134","article-title":"Changes in prostate cancer grade on serial biopsy in men undergoing AS","volume":"29","author":"Porten","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.009_bib33","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1172\/JCI70354","article-title":"Tracking the clonal origin of lethal prostate cancer","volume":"123","author":"Haffner","year":"2013","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.eururo.2013.12.052","article-title":"The lethal clone in prostate cancer: redefining the index","volume":"66","author":"Barbieri","year":"2014","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.009_bib35","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.cell.2015.04.042","article-title":"In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior","volume":"161","author":"Zomer","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.009_bib36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"AS of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large AS cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ucl.2025.09.009_bib38","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1001\/jama.2024.6695","article-title":"Long-term out comes in patients using protocol-directed active surveillance for prostate cancer","volume":"331","author":"Newcomb","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.009_bib39","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","article-title":"A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment","volume":"70","author":"Bokhorst","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.009_bib40","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bju.16436","article-title":"Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN)","volume":"134","author":"Kato","year":"2024","journal-title":"BJU Int"},{"issue":"12","key":"10.1016\/j.ucl.2025.09.009_bib41","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.23502","article-title":"Active surveillance for the management of prostate cancer in a contemporary cohort","volume":"112","author":"Dall\u2019Era","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.009_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2008.09.007","article-title":"Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly","volume":"55","author":"van den Bergh","year":"2009","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.009_bib43","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2016.03.048","article-title":"Long-term results of active surveillance in the g\u00f6teborg randomized, population-based prostate cancer screening trial","volume":"70","author":"Godtman","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.009_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/21681805.2017.1380697","article-title":"Active surveillance for localized prostate cancer: update of a prospective single-center cohort","volume":"52","author":"Thostrup","year":"2018","journal-title":"Scand J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.009_bib45","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2013.02.020","article-title":"Medium-term outcomes of active surveillance for localised prostate cancer","volume":"64","author":"Selvadurai","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.009_bib46","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.eururo.2020.02.009","article-title":"Radical prostatectomy or observation for clinically localized prostate cancer: extended Follow-up of the prostate cancer intervention versus observation trial (PIVOT","volume":"77","author":"Wilt","year":"2020","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ucl.2025.09.009_bib47","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"370","author":"Bill-Axelson","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ucl.2025.09.009_bib48","first-page":"1547","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"Prot Study Group Fifteen-Year Outcomes Monit Surg Radiother Prostate Cancer N Engl J Med"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.009_bib49","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.juro.2016.06.102","article-title":"AS for intermediate risk prostate cancer: survival outcomes in the sunnybrook experience","volume":"196","author":"Musunuru","year":"2016","journal-title":"J Urol"},{"issue":"13","key":"10.1016\/j.ucl.2025.09.009_bib50","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/jnci\/djq154","article-title":"National prostate cancer register (NPCR) of Sweden. Outcomes in localized prostate cancer: National prostate cancer register of Sweden follow-up study","volume":"102","author":"Stattin","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib51","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.juro.2017.03.123","article-title":"Intermediate-term outcomes for men with very low\/low and intermediate\/high risk prostate cancer managed by AS","volume":"198","author":"Nyame","year":"2017","journal-title":"J Urol"},{"issue":"17","key":"10.1016\/j.ucl.2025.09.009_bib52","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","article-title":"20-year outcomes following conservative management of clinically localized prostate cancer","volume":"293","author":"Albertsen","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.009_bib53","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2012.04.024","article-title":"Individualized estimation of the benefit of radical prostatectomy from the Scandinavian prostate cancer group randomized trial","volume":"62","author":"Vickers","year":"2012","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.009_bib54","first-page":"49","article-title":"Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial","volume":"54","author":"Delahunt","year":"2022","journal-title":"Pathology (Phila)"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.009_bib55","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/bco2.195","article-title":"The highest percentage of Gleason pattern 4 is a predictor in intermediate-risk prostate cancer","volume":"4","author":"Sato","year":"2022","journal-title":"BJUI Compass"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.009_bib56","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1097\/PAS.0000000000001345","article-title":"Cases having a gleason score 3+4=7 with <5% of gleason pattern 4 in prostate needle biopsy show similar failure-free survival and adverse pathology prevalence to gleason score 6 cases in a radical prostatectomy cohort","volume":"43","author":"Sato","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.009_bib57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ajcp\/aqad005","article-title":"Significance of the percentage of gleason pattern 4 at prostate biopsy in predicting adverse pathology on radical prostatectomy: application in AS","volume":"160","author":"Ordner","year":"2023","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.009_bib58","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.juro.2011.03.115","article-title":"The potential impact of reproducibility of gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study","volume":"186","author":"McKenney","year":"2011","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.009_bib59","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.juro.2016.01.120","article-title":"Prognostic value of percent gleason grade 4 at prostate biopsy in predicting prostatectomy pathology and recurrence","volume":"196","author":"Cole","year":"2016","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.ucl.2025.09.009_bib60","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.ejca.2014.03.009","article-title":"Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort","volume":"50","author":"Trudel","year":"2014","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib61","article-title":"Prostate cancer with cribriform pattern: exclusion criterion for AS? Arch Ital","volume":"92","author":"Bernardino","year":"2020","journal-title":"Urol Androl"},{"issue":"12","key":"10.1016\/j.ucl.2025.09.009_bib62","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/PAS.0b013e3182a02169","article-title":"Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma","volume":"37","author":"Dong","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.009_bib63","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/modpathol.2016.49","article-title":"Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy","volume":"29","author":"Kweldam","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ucl.2025.09.009_bib64","doi-asserted-by":"crossref","DOI":"10.1111\/bju.16884","article-title":"Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome","author":"Olivier","year":"2025","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib65","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.eururo.2018.08.009","article-title":"Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity","volume":"75","author":"L\u00f8vf","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.009_bib66","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on AS for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"issue":"10071","key":"10.1016\/j.ucl.2025.09.009_bib67","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib68","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/pcan.2016.16","article-title":"Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for AS","volume":"19","author":"Radtke","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib69","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","article-title":"Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on AS (ASIST): 2-year postbiopsy Follow-up","volume":"77","author":"Klotz","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.009_bib70","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.juro.2012.07.024","article-title":"Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for AS of clinically low risk prostate cancer","volume":"188","author":"Vargas","year":"2012","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib71","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","article-title":"Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis","volume":"78","author":"Sathianathen","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib72","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","article-title":"PRECISE version 2: updated recommendations for reporting prostate magnetic resonance imaging in patients on AS for prostate cancer","volume":"86","author":"Englman","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib73","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.euo.2020.09.002","article-title":"Can the use of serial multiparametric magnetic resonance imaging during AS of prostate cancer avoid the need for prostate Biopsies?-A systematic diagnostic test accuracy review","volume":"4","author":"Hettiarachchi","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.009_bib74","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","article-title":"Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during AS: a systematic review and meta-analysis","volume":"80","author":"Rajwa","year":"2021","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.009_bib75","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2018.11.031","article-title":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","volume":"75","author":"Johnson","year":"2019","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.ucl.2025.09.009_bib76","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.7150\/thno.23180","article-title":"Genes involved in prostate cancer progression determine MRI visibility","volume":"8","author":"Li","year":"2018","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.ucl.2025.09.009_bib77","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.3390\/cancers15123074","article-title":"Radiogenomics analysis linking multiparametric MRI and transcriptomics in prostate cancer","volume":"15","author":"Dinis Fernandes","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.ucl.2025.09.009_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12072605","article-title":"Radiogenomics reveals correlation between quantitative texture radiomic features of biparametric MRI and hypoxia-related gene expression in men with localised prostate cancer","volume":"12","author":"Ogbonnaya","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.009_bib79","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41585-022-00587-0","article-title":"The current role of MRI for guiding AS in prostate cancer","volume":"19","author":"Ploussard","year":"2022","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.009_bib80","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41391-018-0111-4","article-title":"The role of prostate imaging reporting and data system score in gleason 3 + 3 AS candidates enrollment: a diagnostic meta-analysis","volume":"22","author":"Zhai","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.009_bib81","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clgc.2022.04.001","article-title":"MRI-detectability of clinically significant prostate cancer relates to oncologic outcomes after prostatectomy","volume":"20","author":"Wibmer","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.009_bib82","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.eururo.2020.03.035","article-title":"Five-year outcomes of magnetic resonance imaging-based AS for prostate cancer: a large cohort study","volume":"78","author":"Stavrinides","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.009_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-024-00932-x","article-title":"Prognostic value of MR visibility\/invisibility in men on active surveillance","author":"Klotz","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"19","key":"10.1016\/j.ucl.2025.09.009_bib84","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2025.3579","article-title":"Microultrasonography-guided vs MRI-guided biopsy for prostate cancer diagnosis: the OPTIMUM randomized clinical trial","volume":"333","author":"Kinnaird","year":"2025","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.009_bib85","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1097\/JU.0000000000001639","article-title":"Micro-ultrasound-guided vs multiparametric magnetic resonance imaging-targeted biopsy in the detection of prostate cancer: a systematic review and meta-analysis","volume":"205","author":"Sountoulides","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.009_bib86","doi-asserted-by":"crossref","DOI":"10.5489\/cuaj.6712","article-title":"Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: a multicenter, prospective analysis","volume":"15","author":"Klotz","year":"2021","journal-title":"Can Urol Assoc J"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.009_bib87","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.juro.2015.12.093","article-title":"Assessing cancer risk on novel 29 MHz micro-ultrasound images of the prostate: creation of the micro-ultrasound protocol for prostate risk identification","volume":"196","author":"Ghai","year":"2016","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.009_bib88","article-title":"68Ga-PSMA PET\/CT evaluation in men enrolled in prostate cancer active surveillance","volume":"95","author":"Pepe","year":"2023","journal-title":"Arch Ital Urol Androl"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.009_bib89","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.euo.2023.05.004","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography\/computed tomography in active surveillance for prostate cancer trial (PASPoRT)","volume":"7","author":"Heetman","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.009_bib90","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12894-023-01219-4","article-title":"Expanding the role of PSMA PET in active surveillance","volume":"23","author":"Jain","year":"2023","journal-title":"BMC Urol"},{"key":"10.1016\/j.ucl.2025.09.009_bib91","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07311-1","article-title":"The predictive value of multiparametric MRI combined with [18F]PSMA-1007 PET\/CT for the pathological upgrade in prostate cancer: a multicenter study","author":"Xue","year":"2025","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.009_bib92","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.eururo.2015.12.032","article-title":"Physical activity and survival after prostate cancer","volume":"70","author":"Friedenreich","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.009_bib93","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nrurol.2016.46","article-title":"Enhancing AS of prostate cancer: the potential of exercise medicine","volume":"13","author":"Galv\u00e3o","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"12","key":"10.1016\/j.ucl.2025.09.009_bib94","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/cncr.35241","article-title":"The prostate cancer active lifestyle study (PALS): a randomized controlled trial of diet and exercise in overweight and Obese men on AS","volume":"130","author":"Wright","year":"2024","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ucl.2025.09.009_bib95","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMcibr2035081","article-title":"Obesity, immunity, and cancer","volume":"384","author":"Rathmell","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.009_bib96","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MOU.0000000000000424","article-title":"Obesity and prostate cancer","volume":"27","author":"Bandini","year":"2017","journal-title":"Curr Opin Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.009_bib97","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jama.2019.20207","article-title":"Effect of a behavioral intervention to increase vegetable consumption on cancer progression among men with early-stage prostate cancer: the MEAL randomized clinical trial","volume":"323","author":"Parsons","year":"2020","journal-title":"JAMA"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T09:12:32Z","timestamp":1766135552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014325000928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0094014325000928"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.009","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Active Surveillance for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}